Viropro is a publicly traded company based in Nevada, founded in 1982. Specializing in the development of cell lines and biopharmaceutical processes, Viropro licenses these manufacturing processes to international partners for the production and distribution of the final products. The company is currently exploring partnerships for its biosimilar cell lines and manufacturing processes in the Biotechnology and Manufacturing industries. Viropro received a $500.00K Convertible Note investment on 25 August 2014. With its focus on innovative biopharmaceutical processes and an emphasis on international partnerships, Viropro presents an intriguing opportunity for potential venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $500.00K | - | 25 Aug 2014 |
No recent news or press coverage available for Viropro.
We care about your data, and we'd love to use cookies make your experience better.
